Eris Lifesciences Limited ("ELL" or "Eris") is a publicly listed Indian pharma company and is a leading player in the domestic branded formulations market. Established in 2007, ELL has been focusing on chronic and sub chronic lifestyle related therapies. ELL is fully integrated business with manufacturing facilities in Guwahati and Gujarat.
As part of its adding strategic growth engines strategy, ELL entered the Indian insulin market in 2022 with joint venture (70% with ELL) with MJ Biopharm. The JV commenced two products and INR 18 crore revenue in first year of operations and currently having monthly run rate of circa INR 5 crore. To achieve annual revenues of INR 1000 crore in near future from Diabetes care portfolio, ELL announced two major back-to-back acquisitions which shall facilitate exports & domestic growth.
Eris has historically leveraged acquisitions to enter new therapies; it entered Neuropsychiatry in 2017 through the acquisition of Strides Shasun's domestic business and entered Dermatology in 2022 through the acquisition of Oaknet Healthcare, followed by brand portfolios from Glenmark and Dr. Reddy's in early 2023.
In November 2023, Eris & Biocon Biologics Limited announced strategic partnership to evaluate ways to strengthen Nephrology and Dermatology business owned by Biocon Biologics using strong footholds of Eris in particular area. As a part of this, ELL acquired Biocon Biologics Branded Formulations' India (BFI) business units of Nephrology and Dermatology on a slump sale basis.
The business includes over 20 mother brands with FY23 Revenue of INR 90 cr and current revenue run-rate of INR 100 cr. The deal consideration is INR 366 crore inclusive of working capital conveyed as part of the deal.
Post deal Eris will become the 2nd largest player in Psoriasis with a market share of 11%. The transaction was partly funded through debt & internal accruals.
This story is from the April 2024 edition of M & A Critique.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the April 2024 edition of M & A Critique.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Cement Sector Consolidation Continues: Orient Cement to be acquired by Adani Group's Ambuja Cement
The shopping spree for the Adani group seems to be unstoppable. Recently, Adani group announced yet another acquisition in the cement space. This time it is Orient Cement Limited.
ITAT held that the reserve created on amalgamation is capital in nature and not taxable as perquisite
Recently, the Income Tax Appellate Tribunal, Mumbai held that the reserve created on amalgamation is capital in nature and not taxable as perquisite.
Mega Consolidation: SeQuent Scientific and Viyash Lifesciences backed by PE Carlyle Group
SeQuent Scientific Limited announced a merger which is expected to create a unique & differentiated platform with leading market position in Animal healthcare segment.
Raymond Group continues Segregation of its Business Verticals
After successful demerger of \"Lifestyle Business,\" Raymond Limited announced yet another restructuring to unlock further value for stakeholders.
Ultratech Cements adds India Cement in its shopping cart
India's Cement Industry is poised for consolidation. In recent past we have seen multiple large & small acquisitions in cement segment for consolidating positions.
Valor Estate Limited: "Diversification" to "Sepration" of Hospitality Business
“From investments in hospitality business, the demerger transaction will enable VEL to start its construction in hospitality”
SIEMENS Energy to be a separate entity in alignment with global strategy
Siemens AG announced its Vision 2020+ which included the spin-off of its Gas & Power [G&P) i.e., Energy Business into Siemens Energy.
Arvind Group separates its Advanced Material Business for independent growth trajectory
Advanced Material Business (AMD) of Arvind Limited focuses on advanced materials and caters to customer needs across the textile value chain, including specialty yarns, fabrics, and ready-made products.
Merger for bail-out from debt obligation
Ind Swift Limited (herein after also referred to as 'ISL' or 'Transferor Company') is engaged in the business of manufacturing of Pharmaceutical Products.
Batliboi Ltd. merging its associate company
Batliboi Limited has a history of collaborations with various foreign technical partners and has subsidiaries like Hydraulic & General Engineers Ltd. and Batliboi International Ltd. In March 2024, the board of Directors of Batliboi Limited accorded their approval for the merger of promoter owned private company with itself.
